Muromonab-CD3
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD3 |
| Clinical data | |
| Trade names | Orthoclone OKT3 |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a605011 |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C6460H9946N1720O2043S56 |
| Molar mass | 146189.98 g·mol−1 |
| (what is this?) (verify) | |
Muromonab-CD3 (brand name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant medication given to reduce acute rejection in people with organ transplants.[1][2] It is a monoclonal antibody targeted at the CD3 receptor,[3] a membrane protein on the surface of T cells. It is the first monoclonal antibody to be approved for clinical use in humans.[2]
- ^ Midtvedt K, Fauchald P, Lien B, Hartmann A, Albrechtsen D, Bjerkely BL, et al. (February 2003). "Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection". Clinical Transplantation. 17 (1): 69–74. doi:10.1034/j.1399-0012.2003.02105.x. PMID 12588325. S2CID 8677441.
- ^ a b Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 937. ISBN 3-8047-1763-2.
- ^ "muromonab-CD3". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.